胃腺癌中 PD-L1 和 HER2 的表达及其预后意义。
PD-L1 and HER2 expression in gastric adenocarcinoma and their prognostic significance.
机构信息
Department of Pathology, the First Affiliated Hospital of Xi'an Jiaotong University, No. 277 Yanta West Road, Xi'an 710061, China.
Department of Pathology, the First Affiliated Hospital of Xi'an Jiaotong University, No. 277 Yanta West Road, Xi'an 710061, China.
出版信息
Dig Liver Dis. 2022 Oct;54(10):1419-1427. doi: 10.1016/j.dld.2022.01.128. Epub 2022 Feb 2.
BACKGROUND
The upregulation of programmed death-ligand 1 (PD-L1) and epidermal growth factor receptor 2 (HER2) may play a role in gastric adenocarcinoma (GAC).
AIM
To study PD-L1 and HER-2 expression and prognosis in GAC.
METHODS
PD-L1 and HER2 expression was determined in tumor tissues of 75 patients with GAC. The correlations between PD-L1, HER2 expression, and clinicopathological factors were analyzed.
RESULTS
The positive expression rate for PD-L1 was 57.3% (43/75) and the HER2 over-expression rate was 17.3% (13/75). PD-L1 expression negatively correlated with the grade of GAC differentiation (r =-0.26, P<0.05). Approximately 85% of HER2-positive GACs were found to be PD-L1-positive and PD-L1 expression positively correlated with HER2 overexpression. The TNM stage and combined HER2 and PD-L1 expression were independent prognostic factors affecting the survival of patients with GAC. The median overall survival and recurrence-free survival of groups I (HER2 overexpression and PD-L1 positive), II (HER2 overexpression and PD-L1 negative), III (No HER2 overexpression and PD-L1 positive) and IV (No HER2 overexpression and PD-L1 negative) were (47 (17-77), 15 (0-44), 81 (62-101), and 78 (60-98) months, respectively.
CONCLUSION
PD-L1 expression is upregulated in more than half of patients with GAC. Anti-PD-L1 treatment combined with anti-HER2 therapy may benefit patients with locally advanced GAC with HER2 overexpression.
背景
程序性死亡配体 1（PD-L1）和表皮生长因子受体 2（HER2）的上调可能在胃腺癌（GAC）中发挥作用。
目的
研究 GAC 中 PD-L1 和 HER-2 的表达与预后。
方法
检测 75 例 GAC 患者肿瘤组织中 PD-L1 和 HER2 的表达情况。分析 PD-L1、HER2 表达与临床病理因素的相关性。
结果
PD-L1 阳性表达率为 57.3%（43/75），HER2 过表达率为 17.3%（13/75）。PD-L1 表达与 GAC 分化程度呈负相关（r=-0.26，P<0.05）。约 85%的 HER2 阳性 GAC 为 PD-L1 阳性，且 PD-L1 表达与 HER2 过表达呈正相关。TNM 分期和联合 HER2 和 PD-L1 表达是影响 GAC 患者生存的独立预后因素。组 I（HER2 过表达和 PD-L1 阳性）、II（HER2 过表达和 PD-L1 阴性）、III（无 HER2 过表达和 PD-L1 阳性）和 IV（无 HER2 过表达和 PD-L1 阴性）的中位总生存期和无复发生存期分别为（47（17-77）、15（0-44）、81（62-101）和 78（60-98）个月。
结论
超过一半的 GAC 患者 PD-L1 表达上调。抗 PD-L1 治疗联合抗 HER2 治疗可能有益于 HER2 过表达的局部晚期 GAC 患者。
Zotero 插件